Form 4: Cabaletta Bio CCO Steve Gavel Buys 22,170 Shares

Cabaletta Bio's Chief Commercial Officer, Steve Gavel, reported the purchase of 22,170 shares of common stock at a weighted average price of $2.265.

Summary

• Steve Gavel, Chief Commercial Officer of Cabaletta Bio, Inc. (CABA), acquired 22,170 shares of common stock.
• The transaction occurred on January 21, 2026.
• The shares were purchased at a weighted average price of $2.265 per share, with prices ranging from $2.26 to $2.27.
• Following this transaction, Steve Gavel beneficially owns 22,170 shares of common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: Insider buying by a Chief Commercial Officer generally indicates management confidence in the company's future performance and valuation, which is a positive signal for investors.

Positives

• Insider buying by a key executive (Chief Commercial Officer) signals confidence in the company's future prospects.
• The purchase was made under a Rule 10b5-1 plan, indicating a pre-planned transaction and reducing concerns about trading on immediate non-public information.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction for Cabaletta Bio, a biotechnology company, reflects an executive's personal investment decision. While not directly indicative of broader industry trends, insider confidence can influence sentiment within the sector, particularly for development-stage biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders may view the insider purchase as a positive signal, potentially increasing confidence in the stock's future performance and valuation.
• Employees could interpret the Chief Commercial Officer's investment as a sign of strong belief in the company's strategic direction and commercial prospects.

Key Dates

Recommendation

The purchase of a significant number of shares by a Chief Commercial Officer, especially under a Rule 10b5-1 plan, suggests strong insider confidence in Cabaletta Bio's future prospects and current valuation. This often serves as a positive signal for investors, indicating that management believes the stock is undervalued or poised for growth, warranting a 'buy' recommendation.

Keywords

Cabaletta Bio, CABA, Insider Purchase, Form 4, Steve Gavel, Chief Commercial Officer, Stock Acquisition, Biotechnology, Rule 10b5-1